Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID‐19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915‐918

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 93; no. 5; pp. 2626 - 2627
Main Authors Gando, Alejandro, Alexay, Sofia, Galán Núñez, Juan P., Cano, Lucía N., Diez, Roberto A., Costa, Luis A.
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2021
John Wiley and Sons Inc
Subjects
COVID-19
Critical Illness
Erythropoietin
Humans
Letter to the Editor
Letters to the Editor
Recombinant Proteins
SARS-CoV-2
Virology
Online AccessGet full text
ISSN0146-6615
1096-9071
1096-9071
DOI10.1002/jmv.26879

Cover

More Information
Bibliography:SourceType-Scholarly Journals-1
content type line 14
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Correspondence-1
ObjectType-Commentary-2
content type line 23
ISSN:0146-6615
1096-9071
1096-9071
DOI:10.1002/jmv.26879